Shannon O'Brien
Acute Care · Sewell, NJNPI 1154567675
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 239 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$966
- Novo Nordisk$721
- Lilly USA, LLC$588
- Insulet Corporation$267
- Amphastar Pharmaceuticals, Inc.$176
- Tandem Diabetes Care, Inc.$129
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,05599%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 62 | $966 |
| Novo Nordisk | 47 | $721 |
| Lilly USA, LLC | 37 | $588 |
| Insulet Corporation | 11 | $267 |
| Amphastar Pharmaceuticals, Inc. | 11 | $176 |
| Tandem Diabetes Care, Inc. | 6 | $129 |
| Xeris Pharmaceuticals, Inc. | 8 | $125 |
| Dexcom, Inc. | 4 | $111 |
| Madrigal Pharmaceuticals | 5 | $102 |
| Cequr Corporation | 2 | $95 |
| Sanofi-aventis U.S. LLC | 6 | $94 |
| BETA Bionics, Inc. | 4 | $86 |
| Bayer | 4 | $80 |
| Medtronic | 4 | $73 |
| IBSA Pharma Inc. | 4 | $65 |
| Amgen | 4 | $62 |
| Sequel Med Tech, LLC | 2 | $46 |
| Tolmar, Inc. | 3 | $43 |
| Corcept Therapeutics | 2 | $32 |
| AbbVie | 2 | $30 |
| AstraZeneca | 2 | $29 |
| Rhythm Pharmaceuticals, Inc. | 1 | $26 |
| Radius Health, Inc. | 1 | $23 |
| Mannkind Corporation | 1 | $20 |
| RGH Enterprises LLC | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Intuity Medical Inc | 1 | $14 |
How this compares
$4,086 in reported general payments places this provider in the 90th percentile of 656 acute care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 329 | $725,078 |
| MounjaroTirzepatide | 191 | $298,855 |
| TrulicityDulaglutide | 114 | $217,838 |
| JardianceEmpagliflozin | 75 | $115,797 |
| FarxigaDapagliflozin Propanediol | 68 | $97,978 |
| JanuviaSitagliptin Phosphate | 67 | $87,361 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $80,912 |
| Tresiba Flextouch U-100Insulin Degludec | 63 | $77,824 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 56 | $64,812 |
| Bydureon BciseExenatide Microspheres | 36 | $60,198 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $44,077 |
| RybelsusSemaglutide | 19 | $43,661 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $39,954 |
| Humalog Kwikpen U-100Insulin Lispro | 80 | $32,418 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 163 | $28,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $721 | $781,464381 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $588 | $542,525356 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $15 | $146,148107 claims |
| AstraZenecaFarxiga | $29 | $97,97868 claims |
| Sanofi-aventis U.S. LLCLantus | $94 | $2,33215 claims |
| AbbVieSynthroid | $30 | $1,70720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 656 acute care providers in New Jersey.
Other acute care in Sewell
- Nicole GalatiSewell$6K
- Gabriella MagarelliHackensack$44K
- Per RosenkvistLivingston$29K
- Matthew OstroffPaterson$27K
- Ellen McCueNeptune$26K
- Suzanne ShuggLivingston$25K
- Maria Tedi CoronelHackensack$19K
- Hanane ChaibainouWestampton$16K
- Jennifer McCarthyNewark$16K
- Jennifer HarrarCamden$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.